News


All series


All News

Ecaterina E. Ileana Dumbrava, MD, provides background information on a phase 1/2 study of the agent alone and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors.

Multiple PI3K inhibitors are approved for the treatment of patients with follicular lymphoma in the relapsed or refractory setting, but these targeted treatments are usually given indefinitely, leading to toxicity and increased cost for patients.

This week, the FDA granted Priority Review designation to 4 therapies. The designations were across multiple malignancies and cancer-related conditions, including for patients with post-transplant complications, gastric/gastroesophageal junction and esophageal adenocarcinoma, as well as with squamous cell carcinoma of the anal canal.